Bavarian Nordic defies new failure and maintains efforts in cancer area

Even though Bavarian Nordics' phase II trial with a vaccine candidate against the cancer disease chordoma failed, the firm's management sees enough potential within the oncology portfolio to keep the work going, although it is still uncertain how this will pan out.
Bavarian Nordic's Executive Vice President and Chief Scientific Officer Paul Chaplin. | Photo: Bavarian Nordic / PR
Bavarian Nordic's Executive Vice President and Chief Scientific Officer Paul Chaplin. | Photo: Bavarian Nordic / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

In recent years, Bavarian Nordic has had some trouble in the cancer area with three failures to follow. Firstly, Prostvac, then CV301 and in December 2020 BN-Brachyury failed as a therapeutic vaccine against he rare cancer disease chordoma.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading